

CLINICALLY SIGNIFICANT FINDINGS (4)

CYP2C9 INTERMEDIATE METABOLIZER

*1/*2

Affected drugs: Warfarin, Phenytoin, Celecoxib, Flurbiprofen, Losartan, Simvastatin

CPIC: Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective

This result signifies that the patient has one copy of a normal function allele and one copy of a decreased function allele. Based on the genotype res

CYP3A5 INTERMEDIATE METABOLIZER

*1/*3

Affected drugs: Tacrolimus, Sirolimus

CPIC: Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Us

This result signifies that the patient has one copy of a normal function allele and one copy of a no function allele. Patients with this genotype are

CYP2B6 INTERMEDIATE METABOLIZER

*1/*9

Affected drugs: Efavirenz, Bupropion, Methadone, Cyclophosphamide

CPIC: Initiate efavirenz with standard dosing (600 mg/day)

This result signifies that the patient has one copy of a normal function allele and one copy of a no function allele OR one copy of a normal function

ABCG2 DECREASED FUNCTION

rs2231142 reference (G)/rs2231142 variant (T)

Affected drugs: Rosuvastatin, Sulfasalazine, Methotrexate, Allopurinol

This result signifies that the patient has one copy of a normal function allele and one copy of a no decreased allele. Based on the genotype result,

NORMAL METABOLISM (7 genes — no dosing adjustments needed)

CFTR • CYP2C19 • DPYD • NUDT15 • SLCO1B1 • TPMT • UGT1A1

CLINICAL DISCLAIMER

This report is derived from consumer microarray genotyping with statistical imputation (Beagle 5.5, 1000 Genomes Phase 3). It does not replace clinical-grade pharmacogenomic testing. Phenotype assignments may not be fully resolved from array data. Confirmatory testing via a validated PGx panel is recommended before modifying prescriptions. Results should be interpreted by a qualified healthcare professional in clinical context.